3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Carcinoma, Non-Small-Cell Lung
29
Carcinoma, Transitional Cell
25
Urinary Bladder Neoplasms
24
Neoplasms
22
Carcinoma, Merkel Cell
20
Neoplasm Metastasis
18
Carcinoma, Renal Cell
17
Colorectal Neoplasms
16
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
9
Melanoma
9
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Recurrence
6
Carcinoma, Hepatocellular
6
Ureteral Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Urethral Neoplasms
4
Sarcoma
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Carcinoma, Squamous Cell
4
Uterine Cervical Neoplasms
3
Turcot syndrome
3
Skin Neoplasms
3
Interventions
Cyclophosphamide
193
fludarabine phosphate
121
Peripheral Blood Stem Cell Transplantation
106
Etoposide
106
Mycophenolic Acid
94
Filgrastim
91
Doxorubicin
85
Whole-Body Irradiation
83
Tacrolimus
80
Melphalan
78
Brentuximab Vedotin
77
Busulfan
74
Radiotherapy
73
fludarabine
67
Cyclosporine
67
Vinblastine
65
Rituximab
60
Dacarbazine
56
Granulocyte Colony-Stimulating Factor
53
Gemcitabine
52
Antilymphocyte Serum
51
Bleomycin
50
Nivolumab
47
Methotrexate
47
Vincristine
46
Prednisone
45
Cytarabine
43
pembrolizumab
36
Carmustine
36
Bendamustine Hydrochloride
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Hodgkin Disease
×
avelumab
×
Clear all
NCT03617666
2023-12-12
AVENuE
University College, London
Phase 2
Unknown
49 enrolled
NCT02603419
2020-04-24
JAVELIN HODGKINS
Pfizer
Phase 1
Terminated
34 enrolled
43 charts